Bounce Or More Bumps? New China Market Data Offer Bit Of Both
Two new sets of data on growth in China’s turbulent pharma sector paint a mixed and complex picture, indicating both challenges and opportunities ahead for multinational and domestic firms in the country.
You may also be interested in...
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Transitionally strong urban hospital market will be cut even deeper, forcing drug makers to actively expand to lower-tiered county hospitals and grassroots clinics for growth.
After bagging initial success in China's county hospital market, Sanofi is now targeting another potentially huge sector to drive growth: urban health service centers. While a policy tailwind to emphasize GPs’ role will help, segmented health insurance coverage, poor care quality, and lack of education will make the company's ambitious goal challenging.